bluebird bio (NASDAQ:BLUE – Get Free Report) had its price objective decreased by Bank of America from $4.00 to $3.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price target points to a potential upside of 328.51% from the stock’s current price.
Other research analysts have also recently issued reports about the stock. Barclays reduced their target price on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. lowered bluebird bio from an “overweight” rating to a “neutral” rating in a research note on Thursday. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of bluebird bio in a research report on Thursday. Finally, Robert W. Baird decreased their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, bluebird bio currently has a consensus rating of “Hold” and an average target price of $4.74.
Check Out Our Latest Stock Report on BLUE
bluebird bio Stock Performance
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Sequoia Financial Advisors LLC bought a new position in bluebird bio in the 4th quarter worth approximately $37,000. Cerity Partners LLC acquired a new position in shares of bluebird bio during the fourth quarter valued at $82,000. New York State Common Retirement Fund raised its stake in shares of bluebird bio by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 190,685 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 76,490 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in bluebird bio in the fourth quarter worth about $207,000. Finally, BNP Paribas Financial Markets lifted its holdings in bluebird bio by 144.7% in the fourth quarter. BNP Paribas Financial Markets now owns 524,963 shares of the biotechnology company’s stock worth $724,000 after purchasing an additional 310,461 shares during the period. Institutional investors own 87.43% of the company’s stock.
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Further Reading
- Five stocks we like better than bluebird bio
- What Are Some of the Best Large-Cap Stocks to Buy?
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Most active stocks: Dollar volume vs share volume
- Jeff Brown’s Exegesis AI Stock Picks
- Consumer Staples Stocks, Explained
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.